Bank of America Analysts Give GlaxoSmithKline (LON:GSK) a GBX 1,900 Price Target

Share on StockTwits

Bank of America set a GBX 1,900 ($24.83) price objective on GlaxoSmithKline (LON:GSK) in a report released on Friday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

A number of other analysts also recently weighed in on GSK. Shore Capital reiterated a hold rating on shares of GlaxoSmithKline in a report on Thursday, August 22nd. Citigroup reiterated a neutral rating on shares of GlaxoSmithKline in a report on Tuesday, September 3rd. HSBC set a GBX 2,110 ($27.57) price target on GlaxoSmithKline and gave the stock a buy rating in a report on Tuesday, September 10th. Liberum Capital reiterated a hold rating on shares of GlaxoSmithKline in a report on Friday, August 23rd. Finally, Barclays reiterated an equal weight rating on shares of GlaxoSmithKline in a report on Friday. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and three have issued a buy rating to the stock. GlaxoSmithKline presently has an average rating of Hold and a consensus target price of GBX 1,701.79 ($22.24).

LON GSK opened at GBX 1,642.36 ($21.46) on Friday. The company has a market capitalization of $81.93 billion and a price-to-earnings ratio of 18.50. GlaxoSmithKline has a twelve month low of GBX 1,408.80 ($18.41) and a twelve month high of GBX 1,767 ($23.09). The stock has a fifty day simple moving average of GBX 1,680.89 and a 200 day simple moving average of GBX 1,591.61. The company has a quick ratio of 0.44, a current ratio of 0.71 and a debt-to-equity ratio of 1,127.74.

The firm also recently declared a dividend, which will be paid on Thursday, October 10th. Shareholders of record on Thursday, August 8th will be issued a dividend of GBX 19 ($0.25) per share. The ex-dividend date of this dividend is Thursday, August 8th. This represents a yield of 1.13%. GlaxoSmithKline’s payout ratio is currently 0.86%.

In other GlaxoSmithKline news, insider Vivienne Cox purchased 434 shares of the firm’s stock in a transaction on Wednesday, July 24th. The stock was purchased at an average cost of GBX 1,654 ($21.61) per share, for a total transaction of £7,178.36 ($9,379.80). Over the last quarter, insiders have acquired 457 shares of company stock valued at $755,906.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

See Also: What is the Quick Ratio?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Lloyds Banking Group  Stock Rating Reaffirmed by Jefferies Financial Group
Lloyds Banking Group Stock Rating Reaffirmed by Jefferies Financial Group
Mediclinic International  Rating Reiterated by UBS Group
Mediclinic International Rating Reiterated by UBS Group
Cowen Reaffirms “Buy” Rating for Acceleron Pharma
Cowen Reaffirms “Buy” Rating for Acceleron Pharma
L OREAL CO/ADR  versus A P MOLLER-MAER/ADR  Head to Head Comparison
L OREAL CO/ADR versus A P MOLLER-MAER/ADR Head to Head Comparison
Ocugen  and Its Rivals Head-To-Head Contrast
Ocugen and Its Rivals Head-To-Head Contrast
Head-To-Head Analysis: Putnam Managed Municipal Income Trust  & NeXt Innovation
Head-To-Head Analysis: Putnam Managed Municipal Income Trust & NeXt Innovation


© 2006-2019 Ticker Report